Zhongsheng Tong

Chinese Experts Consensus on the Management of Uncommon Dermatophytosis

Guanzhao Liang, Ge Song, Xiaodong She, Dongmei Shi et autres

cn, ph, th, ca (code pays fourni par la source)

Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial

Huiping Li, Jieqiong Liu, Quchang Ouyang, Shusen Wang et autres

cn (code pays fourni par la source)

PNO1 served as a potential biomarker to promote the stemness and progression of breast cancer via the NF-κB signaling pathway

Xiaorui Wang, Ping Yue, Dongming Liu, Xinrui Wen et autres

cn (code pays fourni par la source)

Abstract PS8-08: Efficacy and safety of SHR-A1811, an anti-HER2 antibody-drug conjugate (ADC), in 391 heavily pretreated multiple solid tumors with HER2-expression or mutations: a global, multi-center, first-in-human, phase 1 study

Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu et autres

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

Quchang Ouyang, Jordi Rodon, Yan Liang, Xinhong Wu et autres

cn, us (code pays fourni par la source)

Adult Kerion Caused by Trichophyton tonsurans

Dong BiLin, Bin Hu, Jing Yang, Zhong Liu et autres

cn (code pays fourni par la source)

Long-Term Efficacy and Safety of Anti-HER2 Antibody-Drug Conjugate SHR-A1811 in Heavily Treated HER2-Expressing or Mutated Advanced Solid Tumours: A Global Phase 1 Trial (HORIZON-X)

Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu et autres

cn, kr, au, us (code pays fourni par la source)

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial

Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu et autres

cn, kr, au, us, tw (code pays fourni par la source)

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: An overall survival update and long-term safety from the randomised, double-blind, placebo-controlled, phase 3 trial.

Jiani Wang, Qingyuan Zhang, Xichun Hu, Qing Li et autres

cn (code pays fourni par la source)

HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer

Yang He, Yue Ma, Ye Zhu, Jingyi Zhang et autres

cn (code pays fourni par la source)

Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial

Binghe Xu, Qingyuan Zhang, Xichun Hu, Qing Li et autres

cn (code pays fourni par la source)

Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients

Yang He, Jing Zhang, Hui Chen, Ying Zhou et autres

cn (code pays fourni par la source)